CAS 1256580-46-7
:Alectinib
Description:
Alectinib is a small molecule drug primarily used in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) gene rearrangements. It functions as a selective inhibitor of ALK, disrupting the signaling pathways that promote tumor growth and survival. Alectinib is characterized by its high potency and specificity for ALK, which helps minimize off-target effects and enhances its therapeutic efficacy. The compound is typically administered orally and has a favorable pharmacokinetic profile, including good absorption and a long half-life, allowing for once or twice daily dosing. Its chemical structure includes a bicyclic core, contributing to its ability to penetrate the blood-brain barrier, making it effective against brain metastases associated with ALK-positive NSCLC. Common side effects may include fatigue, constipation, and liver enzyme elevations, necessitating monitoring during treatment. Overall, Alectinib represents a significant advancement in targeted cancer therapy, offering improved outcomes for patients with specific genetic profiles.
Formula:C30H34N4O2
InChI:InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
InChI key:InChIKey=KDGFLJKFZUIJMX-UHFFFAOYSA-N
SMILES:O=C1C2=C(C(C)(C)C=3C1=CC(CC)=C(C3)N4CCC(CC4)N5CCOCC5)NC=6C2=CC=C(C#N)C6
Synonyms:- 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-
- 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
- Af 802
- Alecensa free base
- Ch 5424802
- Ch 542480210
- Rg 7853
- Rg7853
- Alectinib
- Alectinib (CH5424802)
- AF-802,RG-7853
- CH5424802
- CH5424802-alectinib
- 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile Alectinib (CH5424802)
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
CAS:Formula:C30H34N4O2Purity:98%Color and Shape:SolidMolecular weight:482.6166Alectinib
CAS:Alectinib (RG-7853) is an ALK inhibitor that is selective, orally active, and ATP-competitive. Alectinib has antitumor activity. Cost-effective and quality-assured.Formula:C30H34N4O2Purity:98% - 99.38%Color and Shape:SolidMolecular weight:482.62Alectinib
CAS:<p>Alectinib is a drug that inhibits the activity of tyrosine kinases, including ALK, ROS1, and MET. It binds to ATP-binding sites in the active site of these enzymes and prevents them from transferring phosphate groups onto their substrates. Alectinib also inhibits the activity of polymerase chain reaction (PCR) in vitro by binding to DNA. This drug has been shown to inhibit the growth of lymphoma cells in mice by inhibiting protein synthesis and inducing apoptosis. Alectinib also acts as a p-glycoprotein (Pgp) inhibitor, which may be due to its ability to inhibit an alkaline phosphatase.</p>Formula:C30H34N4O2Purity:Min. 98 Area-%Color and Shape:White PowderMolecular weight:482.62 g/molCH5424802
CAS:Controlled Product<p>Applications CH5424802 is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors. Potent ALK inhibitor<br>References Sakamoto, H., et al.: Cancer Cell., 19, 679 (2011); Kinoshita, K., et al.: Bio-org. Medn., 20, 1271 (2012);<br></p>Formula:C30H34N4O2Color and Shape:NeatMolecular weight:482.62CH5424802-d8
CAS:Controlled Product<p>Applications CH5424802-d8 is the labelled form of CH5424802 (C183360). CH5424802 is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors.<br>References Sakamoto, H., et al.: Cancer Cell., 19, 679 (2011); Kinoshita, K., et al.: Bio-org. Medn., 20, 1271 (2012)<br></p>Formula:C30H26D8N4O2Color and Shape:NeatMolecular weight:490.67
![9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitri…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA000O9H.jpg&w=3840&q=75)
